Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 1/20 | 0.44 |
| ▸ | ITGAV | P06756 | 1/20 | 0.44 |
| ▸ | NTSR1 | P30989 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | MMP1 | P03956 | 1/20 | 0.42 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.40 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.40 |
| ▸ | MMP2 | P08253 | 1/20 | 0.40 |
| ▸ | MMP9 | P14780 | 1/20 | 0.40 |
| ▸ | MMP8 | P22894 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL232948 | 0.98 | ITGB3 (0.45) | ITGB3ITGAVNTSR1CYP3A4CYP2C9 | |
| Leucine SCHEMBL3814957 | 0.90 | ITGB3 (0.45) | ITGB3ITGAVNTSR1CYP3A4CYP2C9 | |
| Leucine SCHEMBL1414045 | 0.89 | ITGB3 (0.47) | ITGB3ITGAVNTSR1CYP3A4CYP2C9 | |
| SCHEMBL7217344 | 0.89 | MAPT (0.53) | ITGB3ITGAVNTSR1CYP3A4CYP2C9 | |
| SCHEMBL7161574 | 0.85 | NPSR1 (0.48) | ITGB3ITGAVNTSR1CYP3A4CYP2C9 | |
| SCHEMBL3194343 | 0.85 | ITGB3 (0.43) | ITGB3ITGAVNTSR1CYP3A4CYP2C9 | |
| SCHEMBL1406185 | 0.84 | GAA (0.38) | ITGB3ITGAVNTSR1CYP3A4CYP2C9 | |
| Alanine SCHEMBL3470608 | 0.84 | NTSR1 (0.39) | NTSR1MEN1KMT2AKEAP1NFE2L2 | |
| SCHEMBL31238101 | 0.83 | PSMB5 (0.54) | ITGB3ITGAVNTSR1CYP3A4CYP2C9 | |
| SCHEMBL5098994 | 0.79 | NTSR1 (0.58) | ITGB3ITGAVNTSR1CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2002101012-A9 | REGULATION OF TRANSGENE EXPRESSION FOLLOWING AAV TRANSDUCTION | CHILDREN S HOSPITAL RES FOUNDA (US) | 2003-12-18 | — | — | WO | claimed |
| US-20030003583-A1 | Regulation of transgene expression following AAV transduction | CHILDREN'S HOSPITAL RESEARCH FOUNDATION | 2003-01-02 | — | — | US | claimed |
| WO-2002101012-A2 | REGULATION OF TRANSGENE EXPRESSION FOLLOWING AAV TRANSDUCTION | CHILDREN'S HOSPITAL RESEARCH FOUNDATION (US) | 2002-12-19 | — | — | WO | claimed |
| US-9963747-B2 | Methods for the identification, assessment, and treatment of patients with cancer therapy | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2018-05-08 | — | — | US | disclosed |
| US-20180117069-A1 | METHODS OF TREATMENT OF CANCER | MILLENNIUM PHARMACEUTICALS, INC. | 2018-05-03 | — | — | US | disclosed |
| US-9827246-B2 | Biomarkers of response to NAE inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-11-28 | — | — | US | disclosed |
| EP-2687608-B1 | Methods for the identification, assessment, and treatment of patients with cancer therapy | MILLENNIUM PHARM INC (US) | 2017-02-08 | — | — | EP | disclosed |
| US-20170023577-A1 | METHODS FOR THE IDENTIFICATION, ASSESSMENT, AND TREATMENT OF PATIENTS WITH PROTEASOME INHIBITION THERAPY | MILLENNIUM PHARM INC (US) | 2017-01-26 | — | — | US | disclosed |
| US-9500656-B2 | Methods for the identification, assessment, and treatment of patients with cancer therapy | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2016-11-22 | — | — | US | disclosed |
| US-20160139132-A1 | Method of Diagnosis or Prognosis of a Neoplasm Comprising Determining the Level of Expression of a Protein in Stromal Cells Adjacent to the Neoplasm | THOMAS JEFFERSON UNIVERSITY (US) | 2016-05-19 | — | — | US | disclosed |
| EP-3021120-A1 | DIAGNOSIS, PROGNOSIS, THERAPEUTICS AND METHODS FOR TREATING NEOPLASTIC DEISEASES COMPRISING DETERMINING THE LEVEL OF CAVEOLIN-1 IN A STROMAL CELL SAMPLE | Lisanti, Michael, P. (US) | 2016-05-18 | — | — | EP | disclosed |
| EP-0979096-B1 | TREATMENT OF INFARCTS THROUGH INHIBITION OF NF-KAPPAB | MILLENNIUM PHARM INC (US) | 2003-05-14 | — | — | EP | disclosed |
| US-20030069189-A1 | Treatment of infarcts | MILLENNIUM PHARMACEUTICALS, INC. | 2003-04-10 | — | — | US | disclosed |
| US-20030003583-A1 | Regulation of transgene expression following AAV transduction | CHILDREN'S HOSPITAL RESEARCH FOUNDATION | 2003-01-02 | — | — | US | disclosed |
| US-20010053760-A1 | Treatment of infarcts | BRAND STEPHEN J (US) | 2001-12-20 | — | — | US | disclosed |
| US-6271199-B2 | Treatment of infarcts | MILLENNIUM PHARMACEUTICALS, INC. | 2001-08-07 | — | — | US | disclosed |
| US-20010002391-A1 | TREATMENT OF INFARCTS | PROSCRIPT, INC. | 2001-05-31 | — | — | US | disclosed |
| EP-0979096-A1 | TREATMENT OF INFARCTS THROUGH INHIBITION OF NF-KAPPAB | PROSCRIPT, INC. (US) | 2000-02-16 | — | — | EP | disclosed |
| WO-1998035691-A9 | TREATMENT OF INFARCTS THROUGH INHIBITION OF NF-KAPPAB | — | 1999-01-14 | — | — | WO | disclosed |
| WO-1998035691-A1 | TREATMENT OF INFARCTS THROUGH INHIBITION OF NF-KAPPAB | PROSCRIPT, INC. (US) | 1998-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180117069-A1 | METHODS OF TREATMENT OF CANCER | RELA, PSMB5, NFKBIA | ITGB3 3996/4885ITGAV 4165/4885NTSR1 3567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.